Glucose-dependent Insulinotropic Polypeptide - New Role as Blood Glucose Stabilizer?

• Status: Completed
• Trial end date: 2014-04-01
• Target enrollment: 0
• Participant gender: Male

Summary

The purpose of this study is to determine whether glucose-dependent insulinotropic polypeptide (GIP) has a stabilizing function on the blood glucose

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: University Hospital, Gentofte, Copenhagen
• Treatments: Gastric Inhibitory Polypeptide

Criteria

Inclusion Criteria:

• Caucasians with T1DM (diagnosed according to WHO's criteria) without residual beta cell function (arginine test without increase in c-peptide) in treatment with long acting insulin OR

• Caucasians with non-insulin treated T2DM (diagnosed according to WHO's criteria) OR

• Caucasians without first degree relative with diabetes mellitus, with normal fasting plasma glucose and glucose tolerance along with negative islet and GAD-65 autoantibodies AND

• Normal hemoglobin

• Informed consent

Exclusion criteria:

• Unwillingness to participate or the wish to leave the present study

• HbA1c > 9 %

• Liver disease (ALAT or ASAT > 2 times normal value)

• Diabetic nephropathy (serum creatinin > 130 microM and/or albuminury)

• Proliferative diabetic retinopathy (anamnetic)

• Atherosclerotic heart disease or heart failure (NYHA group III and IV)

• Anemia

• Treatment with medicine which cannot be paused for 12 hours

• Pregnancy and/or breast feeding

• Fasting plasma glucose > 15 mM on the day of the experiment